Swedish medtech start-up Capitainer has started working with AstraZeneca on a project to use a device for sampling cell-free blood in clinical trial programmes.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh